Redmile Group’s Repare Therapeutics RPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,586,174
Closed -$4.12M 38
2025
Q4
$4.12M Hold
1,586,174
0.3% 30
2025
Q3
$2.79M Hold
1,586,174
0.27% 34
2025
Q2
$2.2M Sell
1,586,174
-298,215
-16% -$389K 0.23% 41
2025
Q1
$1.86M Sell
1,884,389
-31,700
-2% -$38.2K 0.18% 50
2024
Q4
$2.51M Sell
1,916,089
-26,466
-1% -$78.8K 0.17% 51
2024
Q3
$6.68M Hold
1,942,555
0.39% 44
2024
Q2
$6.41M Sell
1,942,555
-73,747
-4% -$263K 0.39% 45
2024
Q1
$9.5M Sell
2,016,302
-132,446
-6% -$849K 0.35% 60
2023
Q4
$15.7M Sell
2,148,748
-255,947
-11% -$1.43M 0.56% 45
2023
Q3
$29M Sell
2,404,695
-23,640
-1% -$244K 1.38% 23
2023
Q2
$25.7M Sell
2,428,335
-104,715
-4% -$1.08M 0.99% 31
2023
Q1
$24.9M Sell
2,533,050
-151,346
-6% -$1.74M 1.08% 36
2022
Q4
$39.5M Hold
2,684,396
1.62% 22
2022
Q3
$32.6M Sell
2,684,396
-36,600
-1% -$471K 1.26% 25
2022
Q2
$38.1M Sell
2,720,996
-12,000
-0.4% -$141K 1.45% 24
2022
Q1
$38.9M Sell
2,732,996
-56,500
-2% -$838K 1.21% 25
2021
Q4
$58.8M Buy
2,789,496
+221,800
+9% +$5.22M 1.34% 21
2021
Q3
$67.4M Sell
2,567,696
-56,700
-2% -$1.83M 1.18% 27
2021
Q2
$81.8M Sell
2,624,396
-41,100
-2% -$1.35M 1.21% 29
2021
Q1
$81.8M Buy
2,665,496
+17,800
+0.7% +$605K 1.15% 28
2020
Q4
$90.8M Buy
2,647,696
+242,722
+10% +$7.25M 1.1% 29
2020
Q3
$74M Buy
2,404,974
+18,800
+0.8% +$498K 1.36% 25
2020
Q2
$74M Buy
+2,386,174
New +$76.6M 1.37% 22

Redmile Group's RPTX Position: Q1 2026 in Review

Redmile Group sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 1,586,174 shares — an estimated $4.12M sold.

Redmile Group first reported a position in RPTX in Q2 2020 and held it in 23 quarters. The position peaked at $90.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.

  • Redmile Group reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Redmile Group sold 1,586,174 Repare Therapeutics shares in Q1 2026, an estimated $4.12M.
  • Redmile Group first reported a position in Repare Therapeutics in Q2 2020 and held it in 23 quarters.
  • Redmile Group's Repare Therapeutics position peaked at $90.8M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.